180 related articles for article (PubMed ID: 26660394)
1. LNK mutations and myeloproliferative disorders.
McMullin MF; Cario H
Am J Hematol; 2016 Feb; 91(2):248-51. PubMed ID: 26660394
[TBL] [Abstract][Full Text] [Related]
2. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L
Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264
[TBL] [Abstract][Full Text] [Related]
3. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
[TBL] [Abstract][Full Text] [Related]
4. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
[TBL] [Abstract][Full Text] [Related]
5. A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosis.
McMullin MF; Wu C; Percy MJ; Tong W
Am J Hematol; 2011 Nov; 86(11):962-4. PubMed ID: 21990094
[TBL] [Abstract][Full Text] [Related]
6. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
7. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
[TBL] [Abstract][Full Text] [Related]
9. Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis.
Luque Paz D; Boyer F; Beucher A; Bouvier A; Jouanneau-Courville R; Guardiola P; Lambert D; Delneste Y; Hunault M; Blanchet O; Ugo V
Blood Cells Mol Dis; 2018 Jul; 71():75-76. PubMed ID: 29703677
[No Abstract] [Full Text] [Related]
10. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
Gery S; Cao Q; Gueller S; Xing H; Tefferi A; Koeffler HP
J Leukoc Biol; 2009 Jun; 85(6):957-65. PubMed ID: 19293402
[TBL] [Abstract][Full Text] [Related]
11. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.
Gery S; Gueller S; Chumakova K; Kawamata N; Liu L; Koeffler HP
Blood; 2007 Nov; 110(9):3360-4. PubMed ID: 17693582
[TBL] [Abstract][Full Text] [Related]
12. Possible new LNK mutations in myeloproliferative neoplasms.
Ha JS; Jeon DS
Am J Hematol; 2011 Oct; 86(10):866-8. PubMed ID: 21922527
[No Abstract] [Full Text] [Related]
13. LNK mutations in JAK2 mutation-negative erythrocytosis.
Lasho TL; Pardanani A; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1189-90. PubMed ID: 20843259
[No Abstract] [Full Text] [Related]
14. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling.
Devallière J; Charreau B
Biochem Pharmacol; 2011 Nov; 82(10):1391-402. PubMed ID: 21723852
[TBL] [Abstract][Full Text] [Related]
15. Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.
Spolverini A; Pieri L; Guglielmelli P; Pancrazzi A; Fanelli T; Paoli C; Bosi A; Nichele I; Ruggeri M; Vannucchi AM
Haematologica; 2013 Sep; 98(9):e101-2. PubMed ID: 23812944
[No Abstract] [Full Text] [Related]
16. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation.
Hurtado C; Erquiaga I; Aranaz P; Miguéliz I; García-Delgado M; Novo FJ; Vizmanos JL
Leuk Res; 2011 Nov; 35(11):1537-9. PubMed ID: 21794913
[No Abstract] [Full Text] [Related]
17. Lnk constrains myeloproliferative diseases in mice.
Bersenev A; Wu C; Balcerek J; Jing J; Kundu M; Blobel GA; Chikwava KR; Tong W
J Clin Invest; 2010 Jun; 120(6):2058-69. PubMed ID: 20458146
[TBL] [Abstract][Full Text] [Related]
18. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
[TBL] [Abstract][Full Text] [Related]
19. Role of the adaptor protein LNK in normal and malignant hematopoiesis.
Gery S; Koeffler HP
Oncogene; 2013 Jun; 32(26):3111-8. PubMed ID: 23045270
[TBL] [Abstract][Full Text] [Related]
20. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M; Gery S; Tabayashi T; Lin D; Alvarez R; Nagler A; Koeffler HP
Br J Haematol; 2013 Jun; 161(6):811-20. PubMed ID: 23590807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
